NAGIOS: RODERIC FUNCIONANDO

Osteochemonecrosis of the jaws due to bisphosphonate treatments : update

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Osteochemonecrosis of the jaws due to bisphosphonate treatments : update

Mostra el registre parcial de l'element

dc.contributor.author Gómez Font, Rafael es
dc.contributor.author Martínez García, María Luisa es
dc.contributor.author Olmos Martínez, José Manuel es
dc.date.accessioned 2017-09-13T10:42:03Z
dc.date.available 2017-09-13T10:42:03Z
dc.date.issued 2008 es
dc.identifier.citation Gómez Font, Rafael ; Martínez García, María Luisa ; Olmos Martínez, José Manuel. Osteochemonecrosis of the jaws due to bisphosphonate treatments : update. En: Medicina oral, patología oral y cirugía bucal. Ed. inglesa, 13 5 2008: 10- es
dc.identifier.uri http://hdl.handle.net/10550/60795
dc.description.abstract Bisphosphonates (BP),were initially used in industry and later as a drug due to their great affinity to osseous tissue, because of their powerful antiresorptive effect as a treatment in various osteopathies, such as osteoporosis, Paget disease or hypercalcemia associated with some malignant tumors, as myeloma or breast cancer. They are administered orally or intravenously, and although well tolerated, the most frequent side effects are gastrointestinal, in addition to osteonecrosis when they are administered via endovenous. The aim of this work has been to evaluate the existing publications in accredited scientific literature on biphosphonates and their action mechanism and the relationship with the appearance of osteonecrosis of the jaws. Although the mechanism by which osteonecrosis of the jaws develops is not known exactly, there seems to be influence by osteoclast inhibiton, antiangiogenic action, an inhibitory effect on the cellular cycle by the keratinocytes, as well as, reinforcement of the chemiotoxic action in oncological patients treated with other drugs. Clinically, it ranges from a non-specificity of symptoms to lesions such as osteomyelitis with necrosis and osseous sequesters that may be accompanied by fetor ex oris, with the appearance of many Actinomyces contaminated lesions. As for published antecedents on osteonecrosis due to bisphosphonate treatment found until 2006: 46.5% had a previous diagnosis of multiple myeloma; 38.8% were patients with metastatic breast cancer; 6.2% patients of metastatic prostate cancer; 4.1% suffered from osteoporosis; 3.5% from other metastatic diseases and 0.8% had Paget disease. The drugs that seem to have the highest incidence of osteochemionecrosis are: zoledronate, pamidronate, alendronate, risendronate and ibandronate, from the greatest to the least. Additionally, the risk of osteonecrosis being produced is accumulative and may reach 21% in the third year of intravenous bisphosphonate use. es
dc.title Osteochemonecrosis of the jaws due to bisphosphonate treatments : update es
dc.type journal article es_ES
dc.subject.unesco UNESCO::CIENCIAS MÉDICAS es
dc.identifier.doi es
dc.type.hasVersion VoR es_ES

Visualització       (294.8Kb)

Aquest element apareix en la col·lecció o col·leccions següent(s)

Mostra el registre parcial de l'element

Cerca a RODERIC

Cerca avançada

Visualitza

Estadístiques